Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRYZT 101

X
Drug Profile

HRYZT 101

Alternative Names: HRYZ T101

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HengRui YuanZheng Bio-Technology
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Nov 2023 Phase-I clinical trials in Solid tumours (Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT05952947)
  • 19 Jul 2023 HengRui YuanZheng Bio-Technology plans a phase I trial for Solid tumors (Second-line therapy or greater, Metastatic disease, Recurrent) in China (IV, Injection) in October 2023 (NCT05952947)
  • 28 Mar 2023 SYZ Cell Therapy plans a phase I trial for Cervical cancer, Head and neck squamous cell carcinoma, Oropharyngeal cancer, Vagina tumor, Penile cancer, Anal cancer, Carcinoma of vulva (Metastatic disease, Recurrent, Second-line therapy or greater) in China (Parenteral, Injection) in March 2023 (NCT05787535)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top